Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Giovannoni, Gavin; Soelberg Sørensen, Per; D. Cook, Stuart; Rammohan, Kottil; Rieckmann, Peter; Comı, Gıancarlo; Dangond, Fernando; Adeniji, Abidemi; Vermersch, Patrick

doi:10.1177/1352458517727603

Public

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Published in Multiple Sclerosis Journal • Sep 5, 2017

Authors:

Gavin Giovannoni

Per Soelberg Sørensen

Stuart D. Cook

Abstract

BACKGROUND: In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing-remitting multiple sclerosis (MS). OBJECTIVE: To assess the safety and efficacy of cladribine treatment in a 2-year Extens...

Subject

Cladribine

Relapsing remitting

Multiple sclerosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!